Hsbc Holdings PLC Arcutis Biotherapeutics, Inc. Transaction History

Hsbc Holdings PLC

$168 Billion
Q3 2024

A detailed history of Hsbc Holdings PLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 12,832 shares of ARQT stock, worth $162,709. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,832

Previous 14,099 8.99%

Holding current value

$162,709

Previous $131,000 9.16%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$8.32 - $11.0 $10,541 - $13,937	-1,267 Reduced 8.99%	12,832 $119,000
Q2 2024 Aug 12, 2024	SELL	$7.24 - $12.53 $3.56 Million - $6.17 Million	-492,187 Reduced 97.22%	14,099 $131,000
Q1 2024 May 15, 2024	BUY	$3.25 - $11.77 $1.18 Million - $4.26 Million	362,351 Added 251.75%	506,286 $5.02 Million
Q3 2023 Nov 13, 2023	SELL	$5.31 - $10.98 $4,672 - $9,662	-880 Reduced 0.61%	143,935 $764,000
Q2 2023 Aug 11, 2023	BUY	$7.51 - $15.0 $174,832 - $349,200	23,280 Added 19.15%	144,815 $1.38 Million
Q1 2023 May 15, 2023	SELL	$10.23 - $17.14 $43,845 - $73,462	-4,286 Reduced 3.41%	121,535 $1.34 Million
Q4 2022 Feb 14, 2023	SELL	$13.96 - $20.4 $68,445 - $100,021	-4,903 Reduced 3.75%	125,821 $1.86 Million
Q3 2022 Nov 14, 2022	BUY	$17.85 - $26.95 $338,560 - $511,160	18,967 Added 16.97%	130,724 $2.5 Million
Q2 2022 Aug 11, 2022	BUY	$16.33 - $22.2 $322,827 - $438,871	19,769 Added 21.49%	111,757 $2.38 Million
Q1 2022 May 16, 2022	BUY	$14.38 - $22.79 $826,346 - $1.31 Million	57,465 Added 166.45%	91,988 $1.77 Million
Q4 2021 Feb 11, 2022	BUY	$14.98 - $25.5 $517,154 - $880,336	34,523 New	34,523 $716,000
Q1 2021 May 14, 2021	SELL	$24.47 - $36.98 $220,474 - $333,189	-9,010 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$17.82 - $31.73 $160,558 - $285,887	9,010 New	9,010 $253,000

Others Institutions Holding ARQT

# of Institutions

197

Shares Held

129M

Call Options Held

738K

Put Options Held

82K

View Full List

About Arcutis Biotherapeutics, Inc.

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $763M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

More about ARQT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Account

Hsbc Holdings PLC Arcutis Biotherapeutics, Inc. Transaction History